Open AccessVirologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings
Author(s) -
Robin M. Nance,
Vani Vannappagari,
Kimberly Y. Smith,
Catherine B. Johannes,
Brian Calingaert,
Catherine W. Saltus,
Kenneth H. Mayer,
Bridget M. Whitney,
Benigno Rodrı́guez,
Richard D. Moore,
Joseph J. Eron,
Elvin Geng,
W. Christopher Mathews,
Michael J. Mugavero,
Michael S. Saag,
Mari M. Kitahata,
Joseph A. Delaney,
Heidi M. Crane
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002075
Subject(s) - dolutegravir , medicine , regimen , darunavir , hazard ratio , discontinuation , proportional hazards model , clinical trial , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , confidence interval
Guidelines for initial antiretroviral treatment (ART) regimens have evolved, with integrase strand transfer inhibitors (INSTIs) increasingly prominent. Research on virologic failure (VF) with INSTI therapy is predominantly from clinical trials not care settings, especially for recently approved medications including dolutegravir. We compared outcomes among people living with HIV (PLWH) who initiated recommended regimens in clinical care across the United States.